New oral drug aims to cut dangerous COPD exacerbations
NCT ID NCT07684820
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This Phase 2 study tests whether a once-daily oral tablet called EXPD-101 can reduce the number of moderate to severe COPD flare-ups in people with chronic bronchitis. Participants must have had at least two moderate or one severe exacerbation in the past year. The trial compares two doses of EXPD-101 against a placebo over 52 weeks, monitoring safety and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EXPD-101 (oral tablet)
- What this could lead to
- If successful, EXPD-101 could become a new daily treatment to reduce the number of serious COPD flare-ups and improve quality of life.
- What could go wrong
- This is a Phase 2 trial, so the drug is still being tested for safety and effectiveness. It may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Burke Internal Medicine, Inc.
RECRUITINGBurke, Virginia, 22015, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
California Medical Research Associates Inc.
RECRUITINGNorthridge, California, 91324, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centricity Research Columbus
NOT_YET_RECRUITINGRincon, Georgia, 31326, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Clinical Site Partners, LLC Leesburg dba Flourish Research
RECRUITINGLeesburg, Florida, 34748, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cotton O'Neil Clinical Research Center
RECRUITINGTopeka, Kansas, 66606, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
DM Clinical Research - Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
DM Clinical Research - Phoenix
RECRUITINGPhoenix, Arizona, 85012, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
DM Clinical Research- Tomball
RECRUITINGTomball, Texas, 77375, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
DM Clinical Research-Indianapolis
RECRUITINGIndianapolis, Indiana, 46254, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lynn Institute of Denver
RECRUITINGAurora, Colorado, 80012, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Optimal Research Sites
RECRUITINGOrange, Florida, 32763, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Suncoast Research Group, LLC Miami - Little Havana dba Flourish Research
RECRUITINGMiami, Florida, 33135, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care
- Could your own lung cells heal COPD? a new stem cell trial aims to find out
- Breathing easy: dynamic x-rays may spot COPD faster and safer
- Common mucus-thinning drugs may improve outcomes in COPD patients with lung cancer
- Could a simple screening strategy uncover hidden TB in COPD patients?
- Routine blood test may reveal hidden clues in COPD emergencies